Floatz logo

TRASTUZUMAB

Locally Advanced Rectal Cancer

Academic and Community Cancer Research Unitedmonoclonal_antibodyPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Locally Advanced Rectal Cancer cohort.

Asset / SponsorPhaseRating
Capecitabine
Seoul National University Hospital
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Institute of Oncology Ljubljana
Phase 2BB
Docetaxel
Institute of Oncology Ljubljana
Phase 2B
Adebrelimab
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2CCC
Fruquintinib
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2CCC
BLEOMYCIN
Zealand University Hospital
Phase 2CCC
Enadenotucirev
University of Oxford
Phase 1CC

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →